RPHPYRO

Presentation: Kit containing 5 vials of lyophilized powder for injection. Sterile, apyrogenic product packaged in a nitrogen atmosphere for complexation with the metastable technetium-99 radioisotope (99mTc).

Indications:It is used primarily in myocardial scintigraphy to evaluate acute myocardial infarction and the extent of necrosis. It can be used as a skeletal imaging agent to demonstrate areas of altered osteogenesis. It can also be used as an agent for blood pool imaging, ventriculography, and studies of
bleed research when administered 20 to 30 minutes after blood labeling.

POSOLOGY AND METHOD OF ADMINISTRATION
Rout of administration: intravenous.
Bone scintigraphy in adults with 70 kg is from 740 MBq (20 mCi) to 1110 MBq (30 mCi).

For myocardial scintigraphy in adults with 70 kg is 740 MBq (15-20 mCi).

Blood pool: in vivo labeling: 555-740 MBq (15-20 mCi) and In vitro: 74-740 MBq (2-20 mCi).

Conditions of storage:
• Pre-labeling: From 2 ºC to 8 ºC, protected from light.
• Post-labeling: room temperature of 15 to 30 ºC, protected from light.
Stability post-labeling: 4 hours in room temperature (15 to 30 ºC)

Product expiration date: 24 months

Number of vials per kit: 5

Registration: MS. 1.7359.0006.001-0

AVAILABLE BY PRESCRIPTION ONLY – RESTRICTED USE TO HOSPITALS.

IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.

Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.